Press release
Epidermolysis Bullosa Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Epidermolysis Bullosa Pipeline Outlook Report [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Epidermolysis Bullosa Pipeline Report
* In July 2025, Castle Creek Biosciences, LLC. announced a study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
* In July 2025, Krystal Biotech, Inc. announced a study (protocol NHS) for at least 12 weeks and that meet all other eligibility criteria receive weekly ophthalmic administration of Investigational product (IP), KB803 or placebo, for the first 12-week intervention period. During the second intervention period subjects will receive the alternative IP for an additional 12 weeks. IP will be administered in the home setting by a healthcare provider.
* DelveInsight's Epidermolysis Bullosa pipeline report depicts a robust space with 20+ active players working to develop 21+ pipeline therapies for Epidermolysis Bullosa treatment.
* The leading Epidermolysis Bullosa Companies such as Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.
* Promising Epidermolysis Bullosa Pipeline Therapies such as diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.
Learn how leading Epidermolysis Bullosa Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Epidermolysis Bullosa Clinical Trials Assessment [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Epidermolysis Bullosa Emerging Drugs Profile
* EB-101: Abeona Therapeutics
EB-101 is an autologous, engineered cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer with severe epidermal wounds that impact the length and quality of their lives. People with RDEB have a defect in the COL7A1 gene, leaving them unable to produce Type VII collagen that helps anchor the dermal and epidermal layers of the skin. In November 2024, Abeona Therapeutics' biologics license application (BLA) for prademagene zamikeracel (pz-cel; EB-101), an investigational autologous gene-corrected epidermal sheet therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), has been accepted for filing by the FDA. The agency has set the Prescription Drug User Fee Act (PDUFA) action date for the BLA for April 29, 2025.
* INM-755: InMed Pharmaceuticals
INM-755 is a cannabinol (CBN) cream intended as a topical therapy to treat symptoms associated with epidermolysis bullosa (EB) and potentially other dermatological diseases. Preclinical data demonstrate that INM-755 (cannabinol) cream may help relieve hallmark EB symptoms, such as pain, inflammation, wound healing and itch, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Epidermolysis Bullosa.
* BM-3103: BioMendics
The company's lead product in development, BM-3103, is a patented topical gel. It is currently being studied in a Phase I/IIa trial for epidermolysis bullosa simplex, with additional indications in the pipeline. MTORX technology is an investigational platform encompassing therapeutic candidate, BM-3103.
The Epidermolysis Bullosa Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.
* Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.
From early-stage research to late-phase Epidermolysis Bullosa Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Epidermolysis Bullosa Treatment Drugs [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Epidermolysis Bullosa Companies
Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.
Epidermolysis bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Epidermolysis Bullosa Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Stay updated with the latest Epidermolysis Bullosa Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Epidermolysis Bullosa Pipeline Report
* Coverage- Global
* Epidermolysis Bullosa Companies- Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma and others.
* Epidermolysis Bullosa Pipeline Therapies- diacerein 1% ointment, allo-APZ2-OTS, Serlopitant Tablet, SD-101-6.0 cream, Oleogel-S10, EB-101, KB803, CX501 and others.
* Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Epidermolysis Bullosa Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Epidermolysis Bullosa Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Epidermolysis bullosa: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* EB-101: Abeona Therapeutics
* Mid Stage Products (Phase II)
* INM-755: InMed Pharmaceuticals
* Early Stage Products (Phase I)
* Drug name: Company name
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Epidermolysis bullosa Key Companies
* Epidermolysis bullosa Key Products
* Epidermolysis bullosa- Unmet Needs
* Epidermolysis bullosa- Market Drivers and Barriers
* Epidermolysis bullosa- Future Perspectives and Conclusion
* Epidermolysis bullosa Analyst Views
* Epidermolysis bullosa Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epidermolysis-bullosa-pipeline-outlook-report-2025-key-20-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epidermolysis Bullosa Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4140709 • Views: …
More Releases from ABNewswire
Fresh Coat Painters of Bonney Lake Introduces Military-Grade Quality Standards f …
Fresh Coat Painters of Bonney Lake introduces military-grade quality standards to residential painting, offering comprehensive interior services, cabinet painting, and industry-leading warranties for Pierce County homeowners.
A veteran-owned painting company in Pierce County is changing how homeowners view contractor reliability. Fresh Coat Painters of Bonney Lake [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-10-16-fresh-coat-painters-of-bonney-lake-introduces-advanced-cabinet-painting-techniques-for-modern-home-transformations] has implemented a systematic approach to residential painting that addresses common frustrations homeowners face when hiring contractors. The company, owned by retired U.S. Air…
What Do Residential Cleaning Services Include? Centerville Cleaning Industry Set …
The Centerville cleaning industry sets comprehensive residential service standards, while Clean & Serene Dayton leads a transformation in professional home cleaning offerings across Montgomery County.
Centerville, OH - Professional residential cleaning standards continue to evolve across Montgomery County as local service providers expand comprehensive offerings to meet growing household demands. Clean & Serene Dayton, LLC, operating from its Centerville headquarters at 10057 Settlement House Rd, reports significant changes in client expectations…
Blessed Transportation Responds to Pacific Northwest Growth with Expanded Charte …
Blessed Transportation expands its service network across Washington State and Portland, addressing growing demand for group transit. The Renton-based operator now serves 13 regional markets with specialized cruise transfers and corporate travel solutions.
The Pacific Northwest continues experiencing population and economic growth, creating increased demand for reliable group transit solutions. Blessed Transportation [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-29-blessed-transportation-achieves-milestone-safety-record-while-delivering-premium-charter-bus-service-across-northwest-washington], operating from Renton, Washington since 2004, has responded by expanding service infrastructure to accommodate rising needs across the…
Moving Companies in Detroit See Surge in Relocations as Professional Movers Deli …
Professional Movers.com delivers 27,493 meals to Michigan food banks while handling increased relocations across Southeast Michigan, demonstrating community leadership during regional economic growth periods.
Local Relocation Activity Increases Across Southeast Michigan
Southeast Michigan's relocation sector shows significant activity as families and businesses adapt to changing economic conditions. Professional Movers.com [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-20-local-family-owned-moving-company-near-me-delivers-over-27000-meals-to-michigan-food-banks-while-expanding-to-three-southeast-michigan-locations] reports handling increased demand across its three locations in Walled Lake, Rochester, and downtown Detroit. The family-owned company, operating since 1978, has…
More Releases for Epidermolysis
Epidermolysis Bullosa Market to Reach USD 6.8 Billion by 2034
Epidermolysis bullosa (EB) is a group of rare, genetic skin disorders characterized by fragile skin that blisters and tears easily. Often referred to as "the butterfly skin disease," EB significantly impacts patients' quality of life and requires long-term supportive care. Historically, treatments were limited to wound management and pain control, but recent advancements in gene therapy, cell-based therapies, and biologics are opening new possibilities for disease-modifying interventions.
Download Full PDF Sample…
Epidermolysis Bullosa Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Epidermolysis Bullosa Research. Learn more about…
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 20 …
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including Epidermolysis Bullosa clinical trials and nonclinical stage products. It also covers the Epidermolysis Bullosa therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Epidermolysis Bullosa Market to Reach US$ 3,856.2 Million by 2033
Market Overview:
The 7 major epidermolysis bullosa markets reached a value of US$ 2,496.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 3,856.2 Million by 2033, exhibiting a growth rate (CAGR) of 4% during 2023-2033.
The report offers a comprehensive analysis of the epidermolysis bullosa market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as…
Singapore Dystrophic Epidermolysis Bullosa Treatment Market to Observe Strong De …
Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine,…
Epidermolysis Bullosa Market Insights, Share, Size, Companies, and Forecast 2032
DelveInsight's Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermolysis Bullosa Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Epidermolysis Bullosa Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size…
